Our #SMARTC collaborative meta-analysis is now in The Lancet Diabetes & Endocrinology: Data from >73,000 people across 12 trials provides the strongest evidence yet for combined use of SGLT2i & GLP-1RA to improve clinical outcomes in diabetes Download free for 50 days here: authors.elsevier.com/a/1jOfA7tNucqx…

#NephJC colleagues are amazing colleagues.

Such a common question - frailty and flozination👇

#NephJC In my mind the key clinical implications. 1. Carefully selected standard criteria living kidney donors can be counselled that donating a kidney will not increase their blood pressure in the subsequent decade beyond what would be expected with normal aging.

T3d Long-term data (we’re talking 45 years+) on patients post nephrectomy suggesting little harm came from World War II veterans who had traumatic nephrectomy had similar survival rate, renal function, hypertension to that of aged-matched controls.#NephJC

Summary of latest publication looking at safety of kidney donation with 7 year follow-up.

Another exciting day in IgA Nephropathy novartis.com/news/media-rel…

Giving a talk. We all know & love the shape of this graph for recent Flozin / Finerenone trials. Can’t find similar graph for older ACEi/ARB trials (RENAAL etc) - anyone have them from the literature? @askrenal #AskRenal

Nice review of one of my least favourite diagnoses. Not sure I believe it accounts for as many as 1 in 20 cases of urinary tract obstruction though…

Welcome to #TenTweetNephJC ✳️10 tweets #NephJC catch-up ✳️ What is the best systolic BP in patients with high-risk CV comorbidities? We reviewed ESPRIT 👻 , in Lancet, comparing SBP 120 vs 140 mmHg in Chinese patients with vascular risks, DM & stroke. pumbmed.ncbi.nlm.nih.gov/38945140/

Last one Tacro or MMF for steroid dependent of frequently relapsing nephrotic syndrome #KidneyWk

APPLAUSE, APPLAUSE Vlado Perkovic Jonathan Barratt Brad H Rovin et al Iptacopan reduces proteinurie (PU) in IgA NP 🐘1: Is the effect additive to SGLT2I (low use in APPLAUSE) 🐘2: How long to treat with iptacopan? 🐘3: Will low PU be longterm renoprotective? nejm.org/doi/full/10.10…

Nice summary from the Oxford Population Health (OxPop) team: “ …while empagliflozin continues to have some benefit after stopping treatment, the effects are smaller than when taking empagliflozin and short lived. Maximising the benefits of such medicines in #CKD requires long-term treatment.’

Nephrology Journal Club .Jen Brown Anand Vaidya we’d love to have authors at our discussion on Bluesky. Chat with Nephrology Journal Club members tomorrow 2/11/25 at 9-10p EST. We have declared February (unofficial) Aldosterone month! Swapnil Hiremath @hswapnil.medsky.social Joel M. Topf, MD FACP

Semaglutide in patients with overweight or obesity and CKD without diabetes #ERA25 Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. nature.com/articles/s4159…